Edgewise Therapeutics

OverviewSuggest Edit

Edgewise Therapeutics is a biotechnology company focused on developing therapies for muscle disorders. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb-girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.

TypePrivate
Founded2017
HQBoulder, CO, US
Websiteedgewisetx.com

Locations

Edgewise Therapeutics is headquartered in
Boulder, United States

Location Map

Latest Updates

Employees (est.) (Dec 2020)19
Share Price (Jun 2021)$26.4

Key People/Management at Edgewise Therapeutics

Kevin Koch

Kevin Koch

President and Chief Executive Officer, Director
Alan Russell

Alan Russell

Co-Founder and Chief Scientific Officer
Behrad Derakhshan

Behrad Derakhshan

Chief Business Officer
Badreddin Edris

Badreddin Edris

Co-Founder & Board Member
Peter Thompson

Peter Thompson

Chairman and Co-Founder
John Moore

John Moore

General Counsel
Show more

Edgewise Therapeutics Office Locations

Edgewise Therapeutics has an office in Boulder
Boulder, CO, US (HQ)
Jennie Smoly Caruthers Biotechnology Building, 3415 Colorado Ave
Show all (1)

Edgewise Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Edgewise Therapeutics total Funding

$50 m

Edgewise Therapeutics latest funding size

$50 m

Time since last funding

2 years ago

Edgewise Therapeutics investors

Edgewise Therapeutics's latest funding round in September 2019 was reported to be $50 m. In total, Edgewise Therapeutics has raised $50 m
Show all financial metrics

Edgewise Therapeutics Revenue

USD

Net income (FY, 2020)

(17.1m)

EBIT (FY, 2020)

(17.2m)

Cash (31-Dec-2020)

104.9m
USDFY, 2019FY, 2020

General and administrative expense

1.3m2.2m

R&D expense

8.6m15.0m

Operating expense total

9.9m17.2m

EBIT

(9.9m)(17.2m)
USDFY, 2019FY, 2020

Cash

23.7m104.9m

Prepaid Expenses

390.0k551.0k

Current Assets

24.0m129.6m

PP&E

498.0k516.0k
USDFY, 2019FY, 2020

Net Income

(9.7m)(17.1m)

Depreciation and Amortization

123.0k185.0k

Accounts Payable

275.0k521.0k

Cash From Operating Activities

(9.2m)(14.6m)
USDFY, 2019

Financial Leverage

1 x
Show all financial metrics

Edgewise Therapeutics Operating Metrics

Mar, 2021

Patent Families

11

Phase I Projects

1

Preclinical Phase Projects

3
Show all operating metrics

Edgewise Therapeutics Online and Social Media Presence

Embed Graph

Edgewise Therapeutics Frequently Asked Questions

  • When was Edgewise Therapeutics founded?

    Edgewise Therapeutics was founded in 2017.

  • Who are Edgewise Therapeutics key executives?

    Edgewise Therapeutics's key executives are Kevin Koch, Alan Russell and Behrad Derakhshan.

  • How many employees does Edgewise Therapeutics have?

    Edgewise Therapeutics has 19 employees.

  • Who are Edgewise Therapeutics competitors?

    Competitors of Edgewise Therapeutics include Rome Therapeutics, ALX Oncology and Sosei Heptares.

  • Where is Edgewise Therapeutics headquarters?

    Edgewise Therapeutics headquarters is located at Jennie Smoly Caruthers Biotechnology Building, 3415 Colorado Ave, Boulder.

  • Where are Edgewise Therapeutics offices?

    Edgewise Therapeutics has an office in Boulder.

  • How many offices does Edgewise Therapeutics have?

    Edgewise Therapeutics has 1 office.